1262523-98-7Relevant articles and documents
Initial experience in synthesis of (2S,4R)-4-[18F]fluoroglutamine for clinical application
Zhang, Yan,Zhang, Lifang,Yang, Jianhua,Wu, Zehui,Ploessl, Karl,Zha, Zhihao,Liu, Fei,Xu, Xiaoxia,Zhu, Hua,Yang, Zhi,Zhu, Lin,Kung, Hank F.
, p. 209 - 214 (2019)
We report initial experience in synthesis of (2S,4R)-4-[18F]fluoroglutamine, [18F]FGln, which has been used as a tool for monitoring glutamine metabolism in cancer patients. [18F]FGln was prepared by a fully automated PET-
Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors
Qu, Wenchao,Zha, Zhihao,Ploessl, Karl,Lieberman, Brian P.,Zhu, Lin,Wise, David R.,Thompson, Craig B.,Kung, Hank F.
, p. 1122 - 1133 (2011/04/16)
A versatile synthetic route to prepare all four stereoisomeric 4-fluoro-glutamines was developed by exploiting a Passerini three-component reaction. The skeleton of 4-substituted glutamine derivatives was efficiently constructed. Subsequent four-step reactions, highlighted by a "neutralized" TASF fluorination, provided the desired products with high yields and excellent optical purity. The optically pure fluorine-18 labeled 4-fluoroglutamines were also successfully prepared using either a 18-crown-6/KHCO3 or K[222]/K2CO3 catalysis system. Preliminary cell uptake and inhibition studies using the 9L tumor cells ana SF188BC1-XL tumor cells (a glutamine addicted tumor derived from glioblastoma) provided strong evidence for their potential application in conjunction with positron emission tomography (PET) for in vivo imaging of tumors, which use glutamine as an alternative energy source.